Advancing Imaging Operations & Analysis in Alzheimer’s Disease Late-Stage Clinical Trials

We cannot play this video. The video is embedded from YouTube, your current cookie preferences do not allow the storing of some of the cookies the player will place.

Phase III clinical trials are required to prove the effectiveness and safety of a drug in a larger population. After decades of research, Alzheimer’s disease still has no disease-modifying drug that is approved as many of the drug development programs fail in later-stage phases. Phase III Alzheimer’s clinical trials face several challenges within imaging operations due to the complexity of the disease and the larger-scale studies. This webinar will address practices to reduce limitations within these operational processes, including:

  • Site qualification optimization
  • Investigator training
  • Patient recruitment
  • Radiological reads

Data management is particularly complex when dealing with large and complex data sets within Phase III trials; therefore, an effective data management platform is required to streamline the processes. This webinar will present the advanced TrialTracker platform for scaling-up processes and systems to manage imaging data, from radiological read workflow to imaging data analysis. Optimised analysis of imaging data is vital for ensuring that the outcomes of the clinical trials are accurately measured and significantly impacts the success and progression of the clinical study. Therefore, this webinar will additionally cover the AI-driven LEAP platform.



Roger Bullock, Chief Medical Officer, Oryzon

Dr. Bullock is considered a world KOL in the space of neurodegenerative diseases. He has extensive experience as clinical researcher, having participated in more than 70 clinical trials in Alzheimer’s disease and other CNS conditions. Over his 30-year research career, he has authored and co-authored more than 100 peer-reviewed publications and book chapters in this domain and presented at numerous conferences. Recently he has been working as a consultant for companies active in the CNS space, including Lilly and Merck.

Shona Clegg, Associate Director Client Services, IXICO

Shona joined IXICO in 2016, and has managed clinical trial projects for clients in a variety of phases and therapeutic areas, including Alzheimer’s, Progressive Supranuclear Palsy and Parkinson’s disease, across a wide range of protocols encompassing MRI, dMRI/ DTI, functional MRI, and PET imaging.  With her extensive operational experience of on-time and on-budget project delivery, Shona’s current role includes quality and service management to help clients achieve their imaging objectives with utmost quality performance.

Richard Joules, Imaging Science Manager, IXICO

Richard has over seven years’ experience working in imaging both in an academic and commercial setting. Holds a PhD from Kings College London in neuroimaging, assessing the application of machine learning to pharmacological resting state fMRI. Richard has worked in a range of therapeutic areas, such Alzheimer’s Disease, Huntington’s Disease and Progressive Supranuclear Palsy, to develop methods for biomarker detection and disease monitoring. As the current imaging science manager at IXICO, he is responsible for the deployment and monitoring of analysis solutions in clinical trials.

Date: 16/11/2020